M&A Deal Summary

Merz Pharma KGaA Acquires BioForm Medical

On January 4, 2010, Merz Pharma KGaA acquired medical products company BioForm Medical from EW Healthcare Partners for 253M USD

Acquisition Highlights
  • This is Merz Pharma KGaA’s 1st transaction in the Medical Products sector.
  • This is Merz Pharma KGaA’s largest (disclosed) transaction.
  • This is Merz Pharma KGaA’s 1st transaction in the United States.
  • This is Merz Pharma KGaA’s 1st transaction in California.

M&A Deal Summary
Date 2010-01-04
Target BioForm Medical
Sector Medical Products
Buyer(s) Merz Pharma KGaA
Sellers(s) EW Healthcare Partners
Deal Type Add-on Acquisition
Deal Value 253M USD
Advisor(s) J.P. Morgan Securities (Financial)
Dewey & LeBoeuf LLP
Ropes & Gray (Legal)

Target

BioForm Medical

San Mateo, California, United States
website
Bioform Medical is a medical device company introducing a family of proprietary, injectable implant products used in minimally invasive soft tissue augmentation procedures. The lead product, Radiesse, will be used for aesthetic/cosmetic indications.

Search 193,605 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Merz Pharma KGaA

Frankfurt am Main, Germany

website

Category Company
Sector Life Science
Revenue 980M USD (2012)
DESCRIPTION

Merz Pharma GmbH & Co. KGaA combines the activities of its three subsidiaries, namely Merz Pharmaceuticals, Merz Consumer Care, and Merz Dental.

DEAL STATS #
Overall 1 of 6
Sector (Medical Products) 1 of 2
Type (Add-on Acquisition) 1 of 5
State (California) 1 of 2
Country (United States) 1 of 4
Year (2010) 1 of 1
Size (of disclosed) 1 of 1
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2013-07-19 Lasya - Intellectual Property Assets

Carrboro, North Carolina, United States

Lasya, Inc. - Intellectual Property Assets includes both U.S. and international patent filings of deoxyArbutin.

Buy -

Seller(S) 1

SELLER

EW Healthcare Partners

Investor Investor Investor Investor Investor

website

Category Growth Capital Firm
Founded 1985
PE ASSETS 3.0B USD
Size Large
Type Sector Focused
DESCRIPTION

Essex Woodlands Health Ventures is a growth equity and venture capital specialist investment firm focused on opportunities across the healthcare sector. Specific areas of interest include biotechnology, pharmaceuticals, medical devices, and healthcare services/IT. Historically, Essex invested primarily in early and later-stage situations; however, today the firm also makes growth capital investments between $20 - $60 million in companies valued between $50 - $250 million, as well as private investments in public entities (PIPEs). Essex Woodlands was formed in 1985 and offices in Palo Alto, California; New York City; Houston, Texas; Shanghai and London.

DEAL STATS #
Overall 16 of 52
Sector (Medical Products) 7 of 23
Type (Add-on Acquisition) 9 of 34
State (California) 6 of 16
Country (United States) 14 of 45
Year (2010) 1 of 7
Size (of disclosed) 10 of 22
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2009-12-15 Molecular Partners

Schlieren, Switzerland

Molecular Partners is a clinical-stage biotech company developing DARP in therapeutics, a new class of custom-built protein drugs designed to address challenges current modalities cannot. Molecular Partners was founded in 2004 and is headquartered in Schlieren, Switzerland.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2010-01-06 InSound Medical

Newark, California, United States

InSound Medical is a developer and manufacturer of hearing devices.

Sell $75M
Mergr

Product

Company

Legal